Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and non-clinical data in lymphoma Marker Therapeutics to r
Canadian Apartment Properties Real Estate Investment Trust (OTC:CDPYF) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants Nicole Dolan - Investor Relations Mark Kenney - P
Avis Budget Group's (CAR) second-quarter 2024 earnings and revenues decrease on a year-over-year basis.
Avis Budget Group, Inc. (NASDAQ:CAR ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants David Calabria - Senior Vice President, Corporate Finance and Treasurer Joseph Fer
The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Avis Budget Group (CAR) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $2.60 per share. This compares to earnings of $11.01 per share a year ago.
PARSIPPANY, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for second quarter 2024 today.
Avis Budget Group, Inc. CAR is set to release earnings results for its second quarter, after the closing bell on Aug. 5, 2024.
Avis Budget (CAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN JOSE, Calif. , July 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
With the recent stock market pullback, you may be taking a look at potential bargains among widely-followed stocks. However, instead of “buying the dip” in what's popular, you may want to take a l
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis
IND follows encouraging findings of necrosis, inflammation and T cell infiltration in tumor biopsy of patient in lowest dose cohort SAN JOSE, Calif. , July 23, 2024 /PRNewswire/ -- Anixa Biosciences,
Canadian housing sector faces an affordability crisis due to demographic, regulatory, and economic conditions. Population growth outpaces housing supply, leading to rising rents and low vacancy rates.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE